Systematic Review

Review and methodological analysis of trials currently testing treatment and

prevention options for COVID-19 globally.

Paraskevi C. Fragkou[1,2,§,*], Drifa Belhadi[3,4,§], Nathan Peiffer-Smadja[3,5,¥], Charalampos

D. Moschopoulos[1,¥], François-Xavier Lescure[3,5], Hannah Janocha[6], Emmanouil

Karofylakis[1], Yazdan Yazdanpanah[3,5], France Mentré[3,4], Chrysanthi Skevaki[2,6],

Cédric Laouénan[3,4,#], Sotirios Tsiodras[1,2,#] on behalf of the ESCMID Study Group for

Respiratory Viruses.

[1] 4th Department of Internal Medicine, Medical School, National and Kapodistrian

University of Athens, Attikon University Hospital, Athens, Greece

[2] European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

Study Group for Respiratory Viruses (ESGREV)

[3] Université de Paris, IAME, INSERM, F-75018 Paris, France

[4] Département d'Epidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat

– Claude-Bernard, AP-HP, 75018 Paris, France

[5] Infectious Diseases Department, Bichat-Claude Bernard Hospital, Assistance-

Publique Hôpitaux de Paris, Paris, France

[6] Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Centre

(UGMLC), Philipps University Marburg, German Centre for Lung Research (DZL)

Marburg, Germany

*Corresponding author: Paraskevi C. Fragkou, 4th Department of Internal Medicine,

Medical School, National and Kapodistrian University of Athens, Attikon University

Hospital, Chaidari, Athens, 12462, Greece. Tel: +306973388299, Fax: +30

2105326446, Email: evita.fragou@gmail.com.

§ Equal contribution as first authors

¥ Equal contribution as second authors

#Equal contribution as senior authors

Abstract word count: 294 words

Main manuscript word count: 3873 words

ABSTRACT

Background: As COVID-19 cases continue to rise globally within an unprecedented

short period of time, solid evidence from large randomised controlled trials is still

lacking. Currently, numerous trials testing potential treatment and preventative

options are undertaken globally.

Objectives: We summarised all currently registered clinical trials examining

treatment and prevention options for COVID-19. Additionally, we evaluated the

quality of the retrieved interventional studies.

Data sources: Clinicaltrials.gov, the Chinese Clinical Trial Registry and the European

Union Clinical Trials Register were systematically searched.

Study eligibility criteria: Registered clinical trials examining treatment and/or

prevention options for COVID-19 were included. No language, country or study

design restrictions were applied. We excluded withdrawn or cancelled studies and

trials not reporting therapeutic or preventative strategies for COVID-19.

Participants and interventions: No restrictions in terms of participants' age and

medical background or type of intervention were enforced.

Methods: The registries were searched using the term "coronavirus" or "COVID-19"

from their inception until 26th March 2020. Additional manual search of the registries

was also performed. Eligible studies were summarised and tabulated. Interventional

trials were methodologically analysed, excluding expanded access studies and trials

testing Traditional Chinese Medicine.

Results: In total, 309 trials evaluating therapeutic management options, 23 studies

assessing preventive strategies and 3 studies examining both were retrieved.

Interventional treatment studies were mostly randomised (n=150, 76%) and open-

label (n=73, 37%) with a median number of planned inclusions of 90 (IQR 40-

200).Major categories of interventions that are currently being investigated are

discussed.

Conclusion: Numerous clinical trials have been registered since the onset of the

COVID-19 pandemic. Summarised data on these trials will assist physicians and

researchers to promote patient care and guide future research efforts for COVID-19

pandemic containment. However, up to the end of March, 2020, significant

information on reported trials was often lacking.

Keywords: SARS-CoV-2; COVID-19; novel coronavirus; pneumonia; treatment;

prevention; antivirals; immunomodulators; anti-inflammatory; clinical trials.

INTRODUCTION

COVID-19 pandemic induced by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) has already affected most countries globally [1]. As of April 12, 2020, more than 1,690,000 COVID-19 cases have been officially reported leading to more than 150,900 deaths worldwide, with numbers constantly rising on a daily basis as the virus continues to spread exponentially [2,3].

The original source of SARS-CoV-2 is still debatable, though phylogenetic data analysis converge into the hypothesis that SARS-CoV-2 has possibly originated from bat SARS-like coronaviruses (CoVs) [4–6]. Human CoVs are positive-sense single-stranded RNA (+ssRNA) viruses belonging to the *Orthocoronavirinae* subfamily [7]. The analysis of viral genome as well as structural and non-structural proteins plays central role in identifying candidate treatment targets [7]. Notably, the SARS-CoV-2 surface spike glycoprotein (S-protein) is a key structural component that controls the viral interaction with hosts' angiotensin I converting enzyme 2 (ACE2) receptor in order to invade human epithelial cells [8]. Moreover, molecules directed against non-structural proteins such as the viral protease or pathways imperative for viral genome replication, alone or along with boosters or regulators of the host's immune system, constitute promising therapeutic strategies[8,9].

Given the steep upsurge of COVID-19 cases worldwide within an unprecedented short period of time, we are still waiting for solid evidence from large randomised controlled trials regarding targeted antiviral treatments. In this systematic review, we aim firstly to summarise the data on all currently tested treatment and prevention options for the COVID-19 disease, and secondly to methodologically analyse and evaluate the quality of the registered interventional studies.

METHODS

Registered clinical trials were systematically searched at the ClinicalTrials.gov database[10], the Chinese Clinical Trial Registry[11] and the European Union Clinical Trials Register [12] from their inception up to 26th March 2020 using the search terms "coronavirus" or "COVID-19". Additional manual search of the registries was performed for possibly unidentified studies. No language, country or study design restrictions were applied. Participants of any age and medical background with or at risk for COVID-19 were included, as were any currently tested intervention related to the treatment or prevention of COVID-19.

We excluded withdrawn or cancelled studies and trials not reporting therapeutic or preventative measures for COVID-19. Eligible studies were summarised and tabulated.

Methodological analysis of the interventional studies was performed. Traditional Chinese Medicine (TCM) and homeopathy were excluded from the in-depth qualitative assessment, as we have no expertise to analyse clinical trials testing these agents that rely on controversial scientific rationale [13,14]. We evaluated the study design, number of planned inclusions and primary outcomes of interventional studies, excluding retrospective and "expanded access" studies. Studies were also analysed according to their primary endpoint, i.e. clinical, virological (viral excretion in clinical samples), radiological (imaging results such as CT-scan or X-rays), or biological / immunological (complete blood count, CR, CD8+/CD4+ T cells count, etc.). This review was conducted according to the PRISMA guidelines [15].

RESULTS

1.   General data retrieved

In total, 335 studies were retrieved, including 309 trials evaluating therapeutic molecules, devices and other management options, 23 studies assessing medications, vaccines under development and other preventive strategies, and 3 studies examining both (Figure 1, Table S1, Table S2). An overview of currently tested therapeutic interventions is presented in Figure 2 and Figure 3.

2.   Main treatment interventions

Protease Inhibitors

Lopinavir is a protease inhibitor (PI) activeagainst human immunodeficiency virus 1 (HIV-1) infection. The main coronavirus proteinase (3C-like proteinase or 3CL^{pro}) plays a key role in processing viral polyproteins [16,17]. PIs effectively inhibit the 3CL^{pro} enzyme, thus posing a possibly potent therapeutic agent against SARS-CoV-2 infection.

PIs have shown effectiveness against SARS-CoV, MERS-CoV and SARS-CoV-2 viruses in *in vitro* susceptibility models [18–21]. During SARS-CoV epidemic, lopinavir boosted by ritonavir (a cytochrome P450-3A4 inhibitor) with or without ribavirin, significantly reduced adverse outcomes including mortality[22]. The MIRACLE trial that examines the efficacy of ritonavir boosted lopinavir combined with recombinant interferon-beta 1b (IFN-β1b) in the treatment of MERS, is currently undertaken in Saudi Arabia and results are pending [23].

For COVID-19, lopinavir/ritonavir combined with or without other agents has been

reported to successfully reduce adverse outcomes in sporadic cases from China [24–

27]. These promising reports have set the ground for numerous trials addressing the

safety and efficacy of PIs in SARS-CoV-2 infection (Table 1). Other PIs that are

currently being assessed are ritonavir boosted ASC09 (a novel PI), cobicistat boosted

darunavir as well as the NS3/4A protease inhibitor danoprevir combined with

ritonavir (Table 1, Table S1).

RNA polymerase inhibitors

SARS-CoV-2 and SARS-CoV RNA-dependent RNA polymerase (RdRp) share 96%

sequence identity; this has justified the assumption that inhibitors effective against

SARS-CoV could have similar inhibitory effects against SARS-CoV-2[28].

Nucleoside analogues compete with natural nucleosides for the RdRp active site, thus

inhibiting the viral genome replication [29].Current research efforts focus on

repurposing older moleculesinCOVID-19 treatment, as their safety profile has already

been documented [30].

Remdesivir (GS-5734^{TM}) is an adenosine analogue with broad-spectrum antiviral

properties [31]. Preclinical data demonstrated the efficacy of remdesivir against

SARS-CoV and MERS-CoV, as it has the potential to outcompete the proofreading

ability of coronavirus exonuclease, and carries a high genetic resistance barrier

[21,28,30,32]. Wang et al. confirmed its *in vitro* efficacy against SARS-CoV-2

[33].Currently, it is investigated in 7 randomised, controlled trials (Table 1, Table S1).

Favipiravir is a nucleoside analogue inhibiting the RNA polymerase, initially

approved for the treatment of novel influenza viruses [34]. It is also effective against a

broad range of viruses, including positive-sense single-stranded RNA viruses [34].

Since there have been some promising *in vitro* results for its efficacy against SARS-

CoV-2, favipiravir is now being investigated in 8 clinical trials.

Ribavirin is a guanosine analogue that inhibits inosine monophosphate dehydrogenase

required for the synthesis of guanosine triphosphate, leading to lethal mutagenesis of

RNA genome [35]. Ribavirin was used in SARS epidemic in combination with either

lopinavir/ritonavir or interferon alpha (IFN-α), and these combinations are currently

recommended by the China National Practice Guidelines for the treatment of severe

COVID-19 [22,36].

Azvudine, an azidocytidine analogue that inhibits viral reverse transcriptase,has been

effective against HIV, hepatitis B and C viruses [37]. Its efficacy against SARS-CoV-

2 is being tested in 3 ongoing clinical trials (Table 1, Table S1). Another nucleoside

analogue   undergoing   investigation   for   COVID-19   pneumonia   is

emtricitabine/tenofovir alafenamide.

Anti-malaria drugs

Chloroquine and hydroxychloroquine are currently licensed for the treatment of

malaria and autoimmune diseases [38]. However, they have also been studied against

several viruses with promising *in vitro* results, never confirmed in humans [39–41].

As weak bases, they are concentrated in acidic intra-cellular organelles, leading to

alkalization and distraction of the low pH-dependent steps of viral replication,

including viral-cell fusion and uncoating [38,40]. Moreover, they impair the terminal

glycosylation of ACE2 receptor in Golgi apparatus, thus inhibiting the viral

penetration into the host cells [42].

As they are accumulated in lymphocytes and macrophages, these drugs reduce

secretion of proinflammatory cytokines, and particularly of tumour necrosis factor

alpha (TNF-α) [41]. Experimental data demonstrated that chloroquine is highly

effective *in vitro* against SARS-CoV-2 in an estimated effective concentration that is

easily achievable with standard dosing regimens [33]. Preliminary results from small

studies suggested the effectiveness of chloroquine, alone or combined with

azithromycin, in viral clearance, inhibition of pneumonia exacerbation, improvement

of lung imaging and shortening of the disease course [43,44]. However, clinical trials

with a control group are needed to provide reliable answers for clinicians.

Immunomodulators and anti-inflammatory drugs

Virus-induced exuberant immune response leading to cytokine storm syndrome (CSS)

and secondary haemophagocytic lymphohistiocytosis (HLH) is probably the

underlying pathogenetic mechanism that leads to critical and often fatal COVID-19

infection [45,46]. Hyperinflammation is associated with acute respiratory distress

syndrome (ARDS) and fulminant multi-organ failure thatarefatal if left untreated. In

this context, immunosuppressors (along with antivirals) may play a key role in

counteracting severe SARS-CoV-2 infection [45].

Preliminary data from COVID-19 patients in China reported significantly higher

interleukin (IL)-6 levels in patients with critical COVID-19 disease than those with

severe or mild disease [47]. Tocilizumab and sarilumab, both humanised monoclonal

antibodies (mAbs) against the IL-6 receptor, are currently evaluated in 14 clinical

trials (Table 1, Table S1); tocilizumab, in particular, improved symptoms and

laboratory parameters in a small retrospective study in China [48]. Various other

molecules oriented against different cytokines, as well as intra- and extra-cellular inflammatory pathways, are currently being tested in COVID-19 including: adalimumab, anti-programmed cell death protein 1 mAbs, bevacizumab, ixekizumab, eculizumab, human recombinant IL-2, inhibitors of NLRP3 inflammasome activation (tranilast), Janus Kinase inhibitors, fingolimod and a recombinant fusion protein targeting an immune pathway checkpoint (CD24Fc).Clinical trials on other immunotherapies (i.e.gimsilumab, siltuximab, lenzilumab and leronlimab) have been proposed, but havenot been registered yet.

Immunomodulators licensed for haematological and rheumatological conditions (such as leflunomide and thalidomide), as well as colchicine that counteracts the assembly of the NLRP3 inflammasome, are also being studied for their therapeutic use against SARS-CoV-2 (Table 1,Table S1) [49].

The immunomodulatory effects of macrolide antibiotics, as well as their pharmacodynamic property to achieve at least 10-fold higher concentrations in epithelial lung fluid than in serum, have led researchers to repurpose them against SARS-CoV-2 (Table 1, Table S1) [50,51]. Preliminary results of a study have shownsignificant viral load reduction in patients treated withhydroxychloroquine plus azithromycin [43].

Corticosteroids are major anti-inflammatory drugs, with a conflicting safety profile in severe viral infections [52]. However, their useis currently recommended by the European Society of Intensive Care Medicine in COVID-19 cases with shock and/or evidence of CSS/HLH and/or mechanically ventilated patients with ARDS [53]. Corticosteroids are being tested in 11 clinical trials (Table 1, Table S1).

233 Finally, immunostimulatory molecules that enhance the hosts' immune response

234 against the invading pathogen, like IFN-α, interferon beta (IFN-β), the recombinant

235 protein produced by DNA-shuffling of IFN-α (novaferon), the inactivated

236 *Mycobacterium* vaccine and thymosin a1, are evaluated as viable therapeutic options

237 in various combinations against SARS-CoV-2 [54].

Membrane fusion inhibitors and inhibitors of ACE2 receptor connection

SARS-CoV-2S-protein bindsACE2 receptor on the epithelial cells' membrane [55].

The host's type II transmembrane serine protease (TMPRSS2) facilitates membrane

fusion and augments viral internalization by cleaving and activating the S-protein

[56,57]. These proteins, being an integral part of the viral life cycle, can be used as

possible therapeutic targets.

ACE inhibitors (ACEi) selectively inhibit ACE1 but not ACE2, as they are

structurally different enzymes [58]. Experimental animal models show that

angiotensin II type 1 receptor blockers (ARBs) and ACEi may up-regulate ACE2

expression; although this raised concerns that ACEi and ARBs may be associated

with a more severe form of COVID-19, there is no evidence supporting that ACE2

up-regulation augments the virulence or the penetration of the virus into the hosts'

cells as of yet [58,59]. Contrarily, renin-angiotensin system (RAS) inhibition may

ameliorate the over-accumulation of angiotensin II induced by the down-regulation of

ACE2 noted in other CoVs infection, thus possibly protecting against the

development of fulminant myocarditis and ARDS [58]. In spite of controversial data,

2 randomised controlled trialstesting losartan are currently undertaken in the USA.

Camostat mesilate is a potent serine protease inhibitor, inhibiting the TMPRSS2 and

is approved for chronic pancreatitis [60]. *In vitro* experiments have shown that

camostat is effective against SARS-CoV-2[61]. Nafamostat, another inhibitor of

TMPRSS2 has been suggested in COVID-19 therapy, but no registered trials are

available yet.

Umifenovir is a small indole derivative with a broad-spectrum antiviral activity

developed about 30 years ago [62,63]. Although it is currently used in Russia and

China to combat influenza, it has shown *in vitro* activity against numerous DNA and

RNA viruses including SARS-CoV [62,64,65]. It primarily targets the interaction

between viral capsid and the membrane of the host cell by inhibiting the attachment,

the fusion and the internalization of the virus [62]. Moreover, umifenovir has direct

virucidal effects against enveloped viruses through interaction with the viral lipid

envelope or with key residues within structural proteins of virions [62,65,66]. Limited

data support that umifenovir may exhibit immunomodulatory effects by stimulating

hosts' humoral immune response, interferon production, and phagocytes' activation

[67]. A small retrospective study in China demonstrated some promising results

regarding its effectiveness against SARS-CoV-2 when used in combination with

lopinavir/ritonavir [68]. Currently 11 relevant clinical trials are in progress globally

(Table 1, Table S1).

Passive immunization

The use of convalescent plasma (CP) to passively immunise patients against viral

pathogens has been previously reported, especially when no other treatment options

wereavailable [69]. CP obtained from recovering patients was usedduringthe SARS

epidemic; two retrospective studies demonstrated that CP administration in SARS

patients reduced duration of hospitalisation and mortality rates, when treatment with

ribavirin and corticosteroids failed [70–72].

A meta-analysis of patients with severe respiratory infection induced by various

viruses showed a statistically significant reduction of 75% in mortality odds in those

who received CP across all viral aetiologies, including the influenza A 2009 pandemic

strain (H1N1pdm09) and SARS-CoV[73]. Evidence of survival benefit was noted

after early administration, while no serious adverse effects were reported. Although

results are pending from 10 relevant clinical trials, the potential short-lasting

immunity after CoV infection has raised uncertaintyregardingthe clinical efficacy of

CP antibodies in clinical practice[74,75].

Cell therapies

Mesenchymal stromal cells (MSCs) exhibit immunomodulating qualities, may skew

immune cell differentiation and have shown promise in H5N1-associated acute lung

injury in preclinical models[76].A pilot study involving MSC transplantation in 7

patients with COVID-19 resulted in cure or significant improvement of pulmonary

function and symptoms without adverse effects [77]. MSCs may partially accumulate

in lungs and improve the pulmonary microenvironment. A significant induction of

regulatory dendritic cells(DCs), along with a shift from Th1 towards Th2 immune

responses,was also observed [77]. Other clinical trials utilizing MSCs for curing

COVID-19 are ongoing (Table 1, Table S1).

MSC-derived exosomes are extracellular bodies mediating intercellular

communication, containing mRNAs, miRNAs, lipids, growth factors and cytokines,

that possibly exert the paracrine immunoregulatory effects of MSC [78]. Furthermore,

MSC-exosomes' administration is associated with lower risks (e.g.tumour formation,

immunogenicity) compared to the intravenous injection of MSCs [79].

Natural killer cells have shown promising results as adoptive immunotherapy in

various cancers, and may also be potent effector cells in the SARS-CoV-2 infection.

A phase 1 clinical trial has been launched to determine their efficacy (Table S1).

Lastly, ozone therapy may inactivate viruses, among other pathogens, and activate the

immune system via up-regulation of Th1 cytokines including IFN and TNF; as such,3

trials have been launched to evaluate ozone autohaemotherapy efficacy in COVID-19

[80].

3.   Main preventative measures

The World Health Organization (WHO) and the European Centre for Disease

Prevention and Control (ECDC) emphasise the role of screening, precaution

measures, exposure prevention and environmental disinfection as the mainstay of

COVID-19 prevention[81,82]. As no effective preventative options are available yet,

several clinical trials are under way to explore the efficacy of various prevention

strategies (Table 2, Table S2).

Many studies are currently evaluating the efficacy of TCM in COVID-19 prevention

in China. Importantly, at least 4 vaccines are under development. Among them, an

mRNA-based vaccine encoding the S-protein is being assessed for its safety,

reactogenicity and efficacy against SARS-CoV-2 (Table 2, Table S2). Besides the

registered trials, other large companies have also announced the initiation of vaccine

development [83,84].

Other preventative molecules include hydroxychloroquine and the recombinant

human interferon α1b spray. In the USA, exposed individuals are randomised to

hydroxychloroquine or placebo, evaluating the agent'spotential as post-exposure

prophylaxis (NCT04308668, Table S2). Furthermore, another randomised clinical

trial evaluates the efficacy of a 3-month course of chloroquine in at-risk healthcare

personnel (NCT04303507, Table S2). Finally, the live attenuated strain of

Mycobacterium bovis is expected to be tested as a preventative strategy against

COVID-19 among healthcare professionals, in Australia and France.

4.   Methodological analysis of interventional studies

Study Populations

In total, 198 interventional treatment and 16prevention trials were included in the

methodological analysis respectively (Table 3). Among the eligible treatment studies,

children recruitment (i.e.< 14 years old) was reported in 7 clinical trials in total: 1

testing darunavir with cobicistat (NCT04252274); 2 on human stem cells transfusion

(ChiCTR2000029606,   ChiCTR2000030944);   1   testing   hydroxycholoroquine

(EudraCT Number: 2020-000890-25); 1 using tocilizumab (NCT04317092); and 1

assessing nutritional supplements (NCT04323345) (Table S1).With respect to

relevant   prevention   studies,   children   were   included   in   2   vaccine

trials(NCT04276896and NCT04299724) as shown in Table S2.

Study designs

Phase IV and phase III treatment trials were the most commonly reported

interventional study types (n=40, 20% and n=35, 18% respectively) as demonstrated

in Table 3. Nonetheless, the majority of registered trials do not disclose the study

phase (n=83, 42%).

In terms of blinding, 73 open-label (37%), 31 double-blinded (16%), and 16 single-

blinded (8%) studies were retrieved. Most trials were randomised (n=150, 76%) with

a parallel assignment between arms. The median (IQR) number of planned inclusions

is 90 (40-200) with a range of 5 to 6000 participants.

Phase III and phase I prevention studies were the most commonly reported ones (n=6,

38% and n=3, 19% respectively, Table3). As with treatment trials, many prevention

trials do not report the study phase (n=4, 25%).

Regarding prevention studies' blinding, 6double-blinded (38%), 5open-label (31%),

and 2 single-blinded (13%) were found. Most studies were randomised (n=10, 63%)

with a parallel assignment design. The median (IQR) number of planned inclusions is

513 (177-2958) ranging from 45 to 7576 participants.

Treatments and interventions

Various types of interventions are currently evaluated; however, their appraisal is

limited by the lack of reported data concerning the treatment dose and duration.

Figure 4 demonstrates the number of trials by the median of planned inclusions per

trial for the ten most frequently encountered therapies. Although remdesivir is tested

in only 7 trials, these studies have the highest median number of planned inclusions

per trial (453, IQR 397-650). On the other hand, cell therapies are assessed by the

highest number of trials (n=25), but with a disproportionately low median number of

planned inclusions (30, IQR 20-60). Figure 5 shows the total number of planned

inclusions and the number of clinical trials for the ten most frequently studied

treatments, with hydroxychloroquine being the treatment associated with the highest

total number (10,146 planned iclusions).

Primary endpoints and outcomes

A clinical primary outcome was defined in 128 therapeutic trials (65%; Table 3); most

of them focused on the symptoms' evolution such as time to clinical recovery, the

proportion of patients with clinical improvement or deterioration, length of

hospitalisation or mortality. A number of scores are utilized as primary outcomes such

as the ordinal 7-point scale adapted from the WHO master protocol, the lung injury

score, the pneumonia severity index or the National Early Warning Score 2 score [85–

87]. Most prevention studies disclose a clinical primary outcome (13 studies, 81%),

while virological, radiological and biological/immunological primary endpoints were

reported in 39 (20%), 19 (10%), and 12 (6%) studies respectively (Table 3).

DISCUSSION

The SARS-CoV-2 is the third emerging coronavirus of the last 20 years, but the one

that has led to an evolving pandemic, a fact that urgently requires the implementation

of novel therapeutics. However, repurposing of existing drugs is a viable and less

time-consuming alternative; licensed broad-spectrum antiviral agents with a well-

documented safety profile are currently tested against SARS-CoV-2. Alternatively,

screening of chemical compounds' libraries may be useful in the discovery of an

efficacious treatment against COVID-19 disease [8]. In this review, we have

summarised and methodologically appraised the ongoing therapeutic and preventive

trials for COVID-19.

Therapeutic strategies should follow the two-phased immune response to COVID-19.

Initially, treatment should aim at strengthening the host's immune response against the

virus, and inhibiting the viral replication [88]. Early initiation of antiviral therapy has

been proved beneficial for the prognosis of patients[89]. As advanced age correlates

with higher viral loads, older patients could strongly benefit from the prompt

initiation of antivirals[90]. Moreover, high inflammatory cytokine levels have been

correlated with disease severity and the extentt of lung damage[91]. Thus, in the later

phase of the infection, patients could be availed by anti-inflammatory therapeutic

approaches such as the Janus kinase inhibitors, blood purification or tocilizumab

[92,93].

The Chinese National Health Commission recommends antiviral therapy with the

protease inhibitors lopinavir/ritonavir. Other recommended antiviral agents include

interferon alpha and chloroquine phosphate [93]. Advantages of chloroquine include

its long clinical history, known side effects and low cost, which render it a good

candidate for global use[33]. The broad-spectrum antiviral agent remdesivir has

successfully been used in individual COVID-19 cases by the Washington Department

of Health[94]. Effectiveness of both chloroquine and remdesivir against COVID-19

remains to be seen in ongoing trials.

Prevention is a key player in combating pandemics. The mRNA 1273 vaccine, is

currently in phase I, but is not expected to be commercially available this year[95].

The prophylactic potential of hydroxychloroquine/chloroquine is also actively being

examined among healthcare professionals[96]. Moreover, prompt testing and isolation

are of utmost importance for disease prevention. At the moment, real-time

quantitative polymerase chain reaction is the reference standard in diagnostics [97].

The FDA has recently announced the authorisation of rapid molecular tests that are

capable of delivering results within minutes, thus facilitating early treatment

initiation(when viral loads are highest) and timely isolation[90,98,99].

Based on the retrieved data, cell therapies and hydroxychloroquine were the most

frequently evaluated candidate therapies (25 and 22 trials respectively), while

remdesivir was associated with the highest median number of planned inclusions per

trial (453, IQR 397-650).Although TCMs and homeopathy represent a large

proportion of the identified interventional studies, we excluded them from our

methodological analysis as we do not have the expertise to analyse clinical trials

testing these agents.

This review shows the considerable amount of clinical trials that are currently

registered. Although the number of identified trials was high, there were several

methodological caveats. Firstly, study design data and details on the interventions

being assessed were often lacking. This hampers the available information to

researchers and relevant stakeholders, and potentially influences the discovery of

successful treatments.

Secondly, most trials, and especially those registered at the beginning of the

pandemic, disclosed low participant numbers, which may impact the robustness of

their future results. However, these numbers should be cautiously interpreted, as they

represent the anticipated, and not the actual number of inclusions. Thirdly, reported

primary endpoints were highly heterogeneous among studies. In our opinion, the

applicationof clinical primary endpoints should be encouraged in an infection where

the association between the clinical status and viral clearance, radiological or

immunological evolution is obscure.

The identification of the best therapeutic approach is challenging, especially in the

context of a pandemic with thousands of casualties. Our study underlines the need to

meticulously register as many study details as possible on international registries

during outbreaks, in order to guide the development and enhance the consistency of

future trials. The development of clinical trials during an outbreak is an adaptive

process and new evidence emerges at an impressive rate. A review of the early

registered clinical trials is an important asset for researchers and methodologists.

These results might encourage transparency when developing and registering future

clinical trials and help improve their methodology, hence the robustness of their

results.

In the absence of reliable vaccines and therapies, disease containment plays a pivotal

role, as has been recently observed in China. Undertaking actions such as nationwide

temperature measurements, health recommendations, detection and strict isolation

proved to slow down the transmission rate [100]. The time thereby won is precious

for the development of therapies and vaccines. This approach is especially useful for

countries with weaker health systems that lack sufficient medical supplies and

infrastructure, and often depend on the support of the international community.

Transparency declaration

Conflict of interest: For YY: Chair of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) and the coordinator of REsearch and ACTion targeting emerging infectious diseases (REACTing).

For CS: Consultancy and research funding, Hycor Biomedical and Thermo Fisher Scientific; Consultancy, BencardAllergie; Research Funding, Mead Johnson Nutrition (MJN). Supported by Universities Giessen and Marburg Lung Centre (UGMLC), the German Centre for Lung Research (DZL), University Hospital Giessen and Marburg (UKGM) research funding according to article 2, section 3 cooperation agreement, and the Deutsche Forschungsgemeinschaft (DFG)-funded-SFB 1021 (C04), -KFO 309 (P10), and SK 317/1-1 (Project number 428518790). All grants are outside the submitted work.

Funding: No external funding was received for this study.

Author contributions: Conception and design: PCF, ST, DB, NPS, FM, CL. Acquisition of data: PCF, EK, CDM, HJ, CS, DB, NPS, YY. Interpretation of data: all authors. Drafting the article: PCF, EK, CDM, HJ, CS, DB, NPS, FM, CL, YY. Revising critically the manuscript for important intellectual content: PCF, CS, ST. PCF and DB contributed equally as first authors, CDM and NPS contributed equally as second authors, CL and ST contributed equally as senior authors. All authors approved the final version of the manuscript submitted.

REFERENCES

[1]   Interim Guidance: Healthcare Professionals 2019-nCoV | CDC n.d.
       https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html
       (accessed April 2, 2020).

491   [2]   Situation reports n.d. https://www.who.int/emergencies/diseases/novel-

492   coronavirus-2019/situation-reports/ (accessed April 2, 2020).

493   [3]   Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in

494   the EU/EEA and the UK – seventh update. n.d.

495   [4]   Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G,

496   Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-

497   nCoV) rejects the hypothesis of emergence as a result of a recent

498   recombination event. Infect Genet Evol 2020;79:104212.

499   https://doi.org/10.1016/j.meegid.2020.104212.

500   [5]   Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and

501   epidemiology of 2019 novel coronavirus: implications for virus origins and

502   receptor binding. Lancet 2020;395:565–74. https://doi.org/10.1016/S0140-

503   6736(20)30251-8.

504   [6]   Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M.

505   The 2019-new coronavirus epidemic: Evidence for virus evolution. J Med

506   Virol 2020;92:455–9. https://doi.org/10.1002/jmv.25688.

507   [7]   Harrison C. Coronavirus puts drug repurposing on the fast track. Nat

508   Biotechnol 2020. https://doi.org/10.1038/d41587-020-00003-1.

509   [8]   Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV).

510   Biosci Trends 2020;14:69–71. https://doi.org/10.5582/bst.2020.01020.

511   [9]   Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A

512   systematic review. J Med Virol 2020;92:479–90.

513   https://doi.org/10.1002/jmv.25707.

514   [10]   Home - ClinicalTrials.gov n.d. https://clinicaltrials.gov/ (accessed April 2,

515   2020).

[11]   Chinese Clinical Trial Register (ChiCTR) - The world health organization

international clinical trials registered organization registered platform n.d.

http://www.chictr.org.cn/searchprojen.aspx (accessed April 2, 2020).

[12] EU Clinical Trials Register - Update n.d. https://www.clinicaltrialsregister.eu/

(accessed April 2, 2020).

[13] Hard to swallow. Nature 2007;448:105–6. https://doi.org/10.1038/448106a.

[14] Ernst E. Homeopathy, a "helpful placebo" or an unethical intervention? Trends

Pharmacol Sci 2010;31:1. https://doi.org/10.1016/j.tips.2009.10.005.

[15] Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al.

Preferred reporting items for systematic reviews and meta-analyses: The

PRISMA statement. PLoS Med 2009;6.

https://doi.org/10.1371/journal.pmed.1000097.

[16] Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, et al. α-Ketoamides as

Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication:

Structure-Based Design, Synthesis, and Activity Assessment. J Med Chem

2020. https://doi.org/10.1021/acs.jmedchem.9b01828.

[17] Fan K, Wei P, Feng Q, Chen S, Huang C, Ma L, et al. Biosynthesis,

purification, and substrate specificity of severe acute respiratory syndrome

coronavirus 3C-like proteinase. J Biol Chem 2004;279:1637–42.

https://doi.org/10.1074/jbc.M310875200.

[18] Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S.

Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-

CoV 3CL(pro) inhibitors. J Theor Biol 2008;254:861–7.

https://doi.org/10.1016/j.jtbi.2008.07.030.

[19] Chen F, Chan KH, Jiang Y, Kao RYT, Lu HT, Fan KW, et al. In vitro

susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral

compounds. J Clin Virol 2004;31:69–75.

https://doi.org/10.1016/j.jcv.2004.03.003.

[20]   de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van

Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-approved compound

library identifies four small-molecule inhibitors of Middle East respiratory

syndrome coronavirus replication in cell culture. Antimicrob Agents

Chemother 2014;58:4875–84. https://doi.org/10.1128/AAC.03011-14.

[21]   Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al.

Comparative therapeutic efficacy of remdesivir and combination lopinavir,

ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:222.

https://doi.org/10.1038/s41467-019-13940-6.

[22]   Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al.

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and

clinical findings. Thorax 2004;59:252–6.

https://doi.org/10.1136/thorax.2003.012658.

[23]   Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et

al. Treatment of Middle East Respiratory Syndrome with a combination of

lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a

randomized controlled trial. Trials 2018;19:81. https://doi.org/10.1186/s13063-

017-2427-0.

[24]   Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. [Management of corona virus

disease-19 (COVID-19): the Zhejiang experience]. Zhejiang Da Xue Xue Bao

Yi Xue Ban 2020;49:0.

[25]   Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. The course of clinical

diagnosis and treatment of a case infected with coronavirus disease 2019. J

Med Virol 2020;92:461–3. https://doi.org/10.1002/jmv.25711.

[26]   Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index

patient who caused tertiary transmission of coronavirus disease 2019 in Korea:

The application of lopinavir/ritonavir for the treatment of COVID-19

pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020;35.

https://doi.org/10.3346/jkms.2020.35.e79.

[27] Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and

therapeutic procedure for four cases with 2019 novel coronavirus pneumonia

receiving combined Chinese and Western medicine treatment. Biosci Trends

2020;14:64–8. https://doi.org/10.5582/bst.2020.01030.

[28] Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent

Prevention and Treatment Options for Severe Acute Respiratory Infections

Caused by 2019-nCoV. Chembiochem 2020;21:730–8.

https://doi.org/10.1002/cbic.202000047.

[29] Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.

Life Sci 2020;248:117477. https://doi.org/10.1016/j.lfs.2020.117477.

[30] Martinez MA. Compounds with therapeutic potential against novel respiratory

2019 coronavirus. Antimicrob Agents Chemother 2020:1–18.

https://doi.org/10.1128/AAC.00399-20.

[31] Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al.

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in

rhesus monkeys. Nature 2016;531:381–5. https://doi.org/10.1038/nature17180.

[32] Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al.

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated

by the Viral Polymerase and the Proofreading Exoribonuclease. MBio 2018;9.

https://doi.org/10.1128/mBio.00221-18.

[33] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and

chloroquine effectively inhibit the recently emerged novel coronavirus (2019-

595   nCoV) in vitro. Cell Res 2020;30:269–71. https://doi.org/10.1038/s41422-020-

596   0282-0.

597 [34] Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure

598   against neglected and emerging RNA viruses. Antiviral Res 2018;153:85–94.

599   https://doi.org/10.1016/j.antiviral.2018.03.003.

600 [35] Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS:

601   A new trick for an old drug? CMAJ 2003;168:1289–92.

602 [36] Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the

603   Epidemiological, Clinical, Preventive and Therapeutic Evidence and

604   Guidelines of Integrative Chinese–Western Medicine for the Management of

605   2019 Novel Coronavirus Disease. Am J Chin Med 2020:1–26.

606   https://doi.org/10.1142/s0192415x20500378.

607 [37] Wang R-R, Yang Q-H, Luo R-H, Peng Y-M, Dai S-X, Zhang X-J, et al.

608   Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug

609   combination features and better inhibition on drug-resistant strains than

610   lamivudine in vitro. PLoS One 2014;9:e105617.

611   https://doi.org/10.1371/journal.pone.0105617.

612 [38] Rolain J-M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl

613   analogue to face bacterial, fungal and viral infections in the 21st century. Int J

614   Antimicrob Agents 2007;30:297–308.

615   https://doi.org/10.1016/j.ijantimicag.2007.05.015.

616 [39] Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res

617   2020;177. https://doi.org/10.1016/j.antiviral.2020.104762.

618 [40] Colson P, Rolain J-M, Raoult D. Chloroquine for the 2019 novel coronavirus

619   SARS-CoV-2. Int J Antimicrob Agents 2020;55:105923.

620   https://doi.org/10.1016/j.ijantimicag.2020.105923.

621   [41]   Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Antiviral effects of

622   chloroquine Effects of chloroquine on viral infections : an old drug against

623   today ' s diseases ? Lancet 2003;3:722–7. https://doi.org/10.1016/S1473-

624   3099(03)00806-5.

625   [42]   Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the

626   antiviral effects of chloroquine. Lancet Infect Dis 2006;6:67–9.

627   https://doi.org/10.1016/S1473-3099(06)70361-9.

628   [43]   Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.

629   Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of

630   an open-label non-randomized clinical trial. Int J Antimicrob Agents

631   2020:105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.

632   [44]   Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown

633   apparent efficacy in treatment of COVID-19 associated pneumonia in clinical

634   studies. Biosci Trends 2020;14:72–3. https://doi.org/10.5582/bst.2020.01047.

635   [45]   Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al.

636   COVID-19: consider cytokine storm syndromes and immunosuppression.

637   Lancet (London, England) 2020;395:1033–4. https://doi.org/10.1016/S0140-

638   6736(20)30628-0.

639   [46]   Chen C, Zhang XR, Ju ZY, He WF. [Advances in the research of cytokine

640   storm mechanism induced by Corona Virus Disease 2019 and the

641   corresponding immunotherapies]. Zhonghua Shao Shang Za Zhi 2020;36:E005.

642   https://doi.org/10.3760/cma.j.cn501120-20200224-00088.

643   [47]   Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical

644   features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie

645   He He Hu Xi Za Zhi 2020;43:203–8. https://doi.org/10.3760/cma.j.issn.1001-

646   0939.2020.03.013.

647 [48] Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective Treatment of

648    Severe COVID-19 Patients with Tocilizumab. n.d.

649 [49] Demidowich AP, Davis AI, Dedhia N, Yanovski JA. Colchicine to decrease

650    NLRP3-activated inflammation and improve obesity-related metabolic

651    dysregulation. Med Hypotheses 2016;92:67–73.

652    https://doi.org/10.1016/j.mehy.2016.04.039.

653 [50] Min J-Y, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators

654    Inflamm 2012;2012:649570. https://doi.org/10.1155/2012/649570.

655 [51] Kanoh S, Rubin BK. Mechanisms of action and clinical application of

656    macrolides as immunomodulatory medications. Clin Microbiol Rev

657    2010;23:590–615. https://doi.org/10.1128/CMR.00078-09.

658 [52] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support

659    corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473–5.

660    https://doi.org/10.1016/S0140-6736(20)30317-2.

661 [53] Important Announcement of new SSC Guidelines – COVID-19 - ESICM n.d.

662    https://www.esicm.org/ssc-covid19-guidelines/ (accessed April 2, 2020).

663 [54] Sallard E, Lescure F-X, Yazdanpanah Y, Mentre F, Peiffer-Smadja N, C-20-15

664    DisCoVeRy French Steering Committee. Type 1 interferons as a potential

665    treatment against COVID-19. Antiviral Res 2020:104791.

666    https://doi.org/10.1016/j.antiviral.2020.104791.

667 [55] Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor

668    blockers in COVID-19 - CEBM n.d. https://www.cebm.net/covid-

669    19/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-receptor-

670    blockers-in-covid-19/ (accessed April 2, 2020).

671 [56] Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of

672    2019-nCoV. Biochem Biophys Res Commun 2020.

https://doi.org/10.1016/j.bbrc.2020.02.071.

[57]   Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S.

TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by

TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome

Coronavirus Spike Protein. J Virol 2014;88:1293–307.

https://doi.org/10.1128/jvi.02202-13.

[58]   Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the

COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-

Angiotensin System Blockers. Hypertens (Dallas, Tex 1979)

2020:HYPERTENSIONAHA12015082.

https://doi.org/10.1161/HYPERTENSIONAHA.120.15082.

[59]   Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is There an

Association Between COVID-19 Mortality and the Renin-Angiotensin System-

a Call for Epidemiologic Investigations. Clin Infect Dis 2020.

https://doi.org/10.1093/cid/ciaa329.

[60]   Yamawaki H, Futagami S, Kaneko K, Agawa S, Higuchi K, Murakami M, et

al. Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy

Improves Epigastric Pain in Early Chronic Pancreatitis and Functional

Dyspepsia with Pancreatic Enzyme Abnormalities. Digestion 2019;99:283–92.

https://doi.org/10.1159/000492813.

[61]   Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S.

The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor

ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv

2020:2020.01.31.929042. https://doi.org/10.1101/2020.01.31.929042.

[62]   Blaising J, Polyak SJ, Pécheur E-I. Arbidol as a broad-spectrum antiviral: an

update. Antiviral Res 2014;107:84–94.

699   https://doi.org/10.1016/j.antiviral.2014.04.006.

700   [63]   Fink SL, Vojtech L, Wagoner J, Slivinski NSJ, Jackson KJ, Wang R, et al. The

701   Antiviral Drug Arbidol Inhibits Zika Virus. Sci Rep 2018;8:8989.

702   https://doi.org/10.1038/s41598-018-27224-4.

703   [64]   Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA,

704   Shoemaker CJ, et al. Arbidol and Other Low-Molecular-Weight Drugs That

705   Inhibit Lassa and Ebola Viruses. J Virol 2019;93.

706   https://doi.org/10.1128/jvi.02185-18.

707   [65]   Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, et al. Antiviral activity of

708   arbidol against influenza A virus, respiratory syncytial virus, rhinovirus,

709   coxsackie virus and adenovirus in vitro and in vivo. Arch Virol

710   2007;152:1447–55. https://doi.org/10.1007/s00705-007-0974-5.

711   [66]   Deng P, Zhong D, Yu K, Zhang Y, Wang T, Chen X. Pharmacokinetics,

712   metabolism, and excretion of the antiviral drug arbidol in humans. Antimicrob

713   Agents Chemother 2013;57:1743–55. https://doi.org/10.1128/AAC.02282-12.

714   [67]   Glushkov RG, Gus'kova TA, Krylova LI, Nikolaeva IS. [Mechanisms of

715   arbidole's immunomodulating action]. Vestn Ross Akad Meditsinskikh Nauk

716   1999:36–40.

717   [68]   Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with

718   LPV/r versus LPV/r alone against Corona Virus Disease 2019:a retrospective

719   cohort study. J Infect 2020. https://doi.org/10.1016/j.jinf.2020.03.002.

720   [69]   Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, et al.

721   Evaluation of convalescent whole blood for treating Ebola Virus Disease in

722   Freetown, Sierra Leone. J Infect 2017;74:302–9.

723   https://doi.org/10.1016/j.jinf.2016.11.009.

[70]   Wong VWS, Dai D, Wu AKL, Sung JJY. Treatment of severe acute respiratory

syndrome with convalescent plasma. Hong Kong Med J 2003;9:199–201.

[71]   Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of

convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin

Microbiol Infect Dis 2005;24:44–6. https://doi.org/10.1007/s10096-004-1271-

9.

[72]   Soo YOY, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KKS, et al.

Retrospective comparison of convalescent plasma with continuing high-dose

methylprednisolone treatment in SARS patients. Clin Microbiol Infect

2004;10:676–8. https://doi.org/10.1111/j.1469-0691.2004.00956.x.

[73]   Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim

WS, et al. The effectiveness of convalescent plasma and hyperimmune

immunoglobulin for the treatment of severe acute respiratory infections of viral

etiology: a systematic review and exploratory meta-analysis. J Infect Dis

2015;211:80–90. https://doi.org/10.1093/infdis/jiu396.

[74]   Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al.

Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV

Infection, Saudi Arabia. Emerg Infect Dis 2016;22:1554–61.

https://doi.org/10.3201/eid2209.151164.

[75]   Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of

antibodies to SARS-associated coronavirus after recovery. N Engl J Med

2007;357:1162–3. https://doi.org/10.1056/NEJMc070348.

[76]   Loy H, Kuok DIT, Hui KPY, Choi MHL, Yuen W, Nicholls JM, et al.

Therapeutic Implications of Human Umbilical Cord Mesenchymal Stromal

Cells in Attenuating Influenza A(H5N1) Virus-Associated Acute Lung Injury. J

Infect Dis 2019;219:186–96. https://doi.org/10.1093/infdis/jiy478.

[77]   Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of

ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with

COVID-19 Pneumonia. Aging Dis 2020;11:216.

https://doi.org/10.14336/ad.2020.0228.

[78]   Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. Int J

Mol Sci 2014;15:4142–57. https://doi.org/10.3390/ijms15034142.

[79]   Yin K, Wang S, Zhao RC. Exosomes from mesenchymal stem/stromal cells: A

new therapeutic paradigm. Biomark Res 2019;7.

https://doi.org/10.1186/s40364-019-0159-x.

[80]   Di Paolo N, Bocci V, Gaggiotti E. Ozone therapy. Int J Artif Organs

2004;27:168–75. https://doi.org/10.1177/039139880402700303.

[81]   Infection prevention and control n.d.

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-

guidance/infection-prevention-and-control (accessed April 2, 2020).

[82]   COVID-19 n.d. https://www.ecdc.europa.eu/en/covid-19-pandemic (accessed

April 2, 2020).

[83]   Moderna's COVID-19 vaccine could reach healthcare workers this fall |

FierceBiotech n.d. https://www.fiercebiotech.com/biotech/moderna-s-covid-19-

vaccine-could-reach-healthcare-workers-fall (accessed April 2, 2020).

[84]   Johnson & Johnson identifies lead COVID-19 vaccine candidate n.d.

https://www.drugtargetreview.com/news/58911/johnson-johnson-identifies-

lead-covid-19-vaccine-candidate/ (accessed April 2, 2020).

[85]   WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial

Synopsis. 2020.

[86]   Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the

adult respiratory distress syndrome. Am Rev Respir Dis 1988;138:720–3.

https://doi.org/10.1164/ajrccm/138.3.720.

[87]   Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A

prediction rule to identify low-risk patients with community-acquired

pneumonia. N Engl J Med 1997;336:243–50.

https://doi.org/10.1056/NEJM199701233360402.

[88]   Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection:

the perspectives on immune responses. Cell Death Differ 2020:1–4.

https://doi.org/10.1038/s41418-020-0530-3.

[89]   Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. Early antiviral treatment

contributes to alleviate the severity and improve the prognosis of patients with

novel coronavirus disease (COVID-19). J Intern Med 2020.

https://doi.org/10.1111/joim.13063.

[90]   To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al.

Temporal profiles of viral load in posterior oropharyngeal saliva samples and

serum antibody responses during infection by SARS-CoV-2: an observational

cohort study. Lancet Infect Dis 2020;3099:1–10.

https://doi.org/10.1016/S1473-3099(20)30196-1.

[91]   Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of

patients infected with 2019 novel coronavirus in Wuhan, China. Lancet

2020;395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.

[92]   Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-

19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis

2020;20:400–2. https://doi.org/10.1016/S1473-3099(20)30132-8.

[93]   Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7) n.d.

http://en.nhc.gov.cn/2020-03-29/c_78469.htm (accessed April 2, 2020).

[94]   Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al.

First case of 2019 novel coronavirus in the United States. N Engl J Med

2020;382:929–36. https://doi.org/10.1056/NEJMoa2001191.

[95] NIH clinical trial of investigational vaccine for COVID-19 begins | National

Institutes of Health (NIH) n.d. https://www.nih.gov/news-events/news-

releases/nih-clinical-trial-investigational-vaccine-covid-19-begins (accessed

April 2, 2020).

[96] Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease

(COVID-19) in the Healthcare Setting - Full Text View - ClinicalTrials.gov

n.d. https://clinicaltrials.gov/ct2/show/NCT04303507 (accessed April 2, 2020).

[97] Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and

diagnosis of COVID-19. J Pharm Anal 2020.

https://doi.org/10.1016/j.jpha.2020.03.001.

[98] Cepheid | Xpert® Xpress SARS-CoV-2 has received FDA Emergency Use

Authorization n.d. https://www.cepheid.com/coronavirus (accessed April 2,

2020).

[99] Detect COVID-19 in as Little as 5 Minutes | Abbott Newsroom n.d.

https://www.abbott.com/corpnewsroom/product-and-innovation/detect-covid-

19-in-as-little-as-5-minutes.html (accessed April 4, 2020).

[100] Report of the WHO-China Joint Mission on Coronavirus Disease 2019

(COVID-19) n.d. https://www.who.int/publications-detail/report-of-the-who-

china-joint-mission-on-coronavirus-disease-2019-(covid-19) (accessed April 2,

2020).

Figures:

Figure 1. Systematic review Flow Chart.

828
829

842 Figure 2. Currently tested therapeutic molecules targeting different steps of SARS-

843 CoV-2 life cycle.

858   Figure 3.General and supportive therapeutic interventions tested for novel coronavirus

859   disease (COVID-19).

Figure 4. Number of trials reported by the median of the total number of planned

inclusions per trial for the most common treatments.

Figure 5. Number of trials per total number of planned inclusions for the ten most

frequently assessed treatments.

Note: The size of the circle corresponds to the addition of the total numbers of

planned inclusions for all trials evaluating one of the treatments

 Tables:

 Table 1. Treatment interventions currently being evaluated for the novel coronavirus

 disease (COVID-19) globally.

Therapeutic Intervention	Countries	No. of trials being tested	No. of RCTs (% of trials per intervention)	Other agents used in combination
TCMs	China	92	61 (66.3)	IFNα, LPV/r, Ribavirin, Chloroquine, Umifenovir, Ulinastatin
Antimalaria drugs (hydroxychloroquine, chloroquine, dihydroartemisinin piperaquine)	China, France, Germany, Mexico, Norway, Spain, Brazil, Canada	34	27 (79.4)	Azithromycin, LPV/r, DRV/r or c, Favipiravir, Oseltamivir, Umifenovir, IFNα
Lopinavir ± ritonavir (LPV ± r)	China, Thailand, Hong Kong, United Kingdom, Europe, South Korea, Canada	32	31 (96.8)	Chloroquine, IFNα, IFNβ, Navaferon, Thymosin a1, FTC/TAF, Ribavirin, Ebastine, Oseltamivir, Favipiravir, TCM
Cell therapy	China, USA, Brazil, Jordan	30	18 (60)	Ruxolitinib
Interferon (IFNα, IFNα2β, IFNβ, rSIFN-co)	China, UK, Hong Kong, Europe	22	22 (100)	Umifenovir, Dihydroartemisinine piperaquine, TCM, Bromhexine, Favipiravir, LPV/r, Ribavirin, Ebastine, Danoprevir/r, Thalidomide, Methylprednisolone, TTF2
Anti-IL-6 mAb (Tocilizumab, Sarilumab)	China, Italy, France, Switzerland, Denmark, USA, Canada, Global	14	9 (64.3)	Favipiravir, Adalimumab
Dietary/Supportive	China, Egypt	13	10 (76.9)	N/A
Corticosteroids	China, UK, Italy	11	9 (81.8)	IFNα Umifenovir, Thalidomide
Umifenovir	China	11	11 (100)	Novaferon, IFNα, IFNα2β, Dihydroartemisinine piperaquine, Bromhexine, Favipiravir, Thalidomide, Methylprednisolone

Convalescent plasma	China, Italy	10	7 (70)	N/A
Adjuvant Device	China	9	3 (33.3)	N/A
Favipiravir	China, Thailand	8	8 (100)	Tocilizumab, Bromhexine, IFNα, Umifenovir, (Hydroxy)chloroquine, LPV/r, DRV/r
Remdesivir	Global, Europe, USA, China	8	7 (87.5)	Hydroxychloroquine
Ventilation/ Oxygenation strategies	China	7	0 (0)	N/A
Macrolides (azithromycin, carrimycin)	China, Brazil, Denmark	4	4 (100)	Hydroxychloroquine
Inhaled Gases	China, USA, Italy	4	4 (100)	N/A
JAK inhibitors (Jakotinib, Ruxolitinib, Baricitinib)	China, Italy, Canada	4	2 (50)	Cell therapy, Ritonavir
ACE inhibitor / ARBs	China, USA	3	2 (66.7)	N/A
Azvudine	China	3	1 (33.3)	N/A
Danoprevir/ritonavir	China	3	3 (100)	IFN
Darunavir/cobicistat (DRV/r)	China, Thailand	3	3 (100)	Thymosin a1, Oseltamivir, Hydroxychloroquine, Favipiravir
Pirferidone	China	3	3 (100)	N/A
Anti-PD-1 mAb	China	3	3 (100)	N/A
Oseltamivir	Thailand, China	3	3 (100)	Hydroxychloroquine, DRV/r, LPV/r
Thymosin a1	China	3	3 (100)	DRV/c, LPV/r
Adalimumab	China	2	2 (100)	Tocilizumab
Bevazicumab	China, Italy	2	1 (50)	N/A
Colchicine	Italy, Canada	2	2 (100)	N/A
Novaferon	China	2	2 (100)	LPV/r, Umifenovir
Ribavirin	China, Hong Kong	2	2 (100)	IFN, LPV/r
Thalidomide	China	2	2 (100)	IFNα, Umifenovir, Methylprednisolone
Ulinastatin	China	2	1 (50)	TCM

ASC09/ritonavir	China	2	2 (100)	N/A
Intravenous Immunoglobulin	China	2	2 (100)	N/A
Acetylcysteine	China	1	1 (100)	N/A
Antiviral peptide LL-37	China	1	0 (0)	N/A
Baloxavir Marboxil	China	1	1 (100)	N/A
Bismuth potassium	China	1	1 (100)	N/A
Bronchoscopic alveolar lavage	China	1	0 (0)	N/A
CD24Fc	USA	1	1 (100)	N/A
Dipyridamole	China	1	1 (100)	N/A
Ebastine	China	1	1 (100)	IFNα, LPV/r
Eculizumab	N/A	1	0 (0)	N/A
Enoxaparin	China	1	1 (100)	N/A
Escin	Italy	1	0 (0)	N/A
Fingolimod	China	1	0 (0)	N/A
FTC/TAF	China	1	1 (100)	LPV/r
hrIL-2	China	1	1 (100)	N/A
Inactivated mycobacterial vaccine	China	1	1 (100)	N/A
Itraconazole	Belgium	1	1 (100)	N/A
Ixekizuman	China	1	1 (100)	IFNα, Ribavirin, Chloroquine, LPV/r, Umifenovir
Leflunomide	China	1	1 (100)	N/A
M1	China	1	1 (100)	N/A
Polyinosinic/ polycytidylic acid	China	1	1 (100)	N/A
rhG-CSF	China	1	1 (100)	N/A
Sargramostin (GM-CSF)	Belgium	1	1 (100)	N/A
Sildenafil	China	1	0 (0)	N/A
Siltuximab	Italy	1	0 (0)	N/A
Suramin	China	1	0 (0)	N/A
T89	N/A	1	1 (100)	N/A

TFF-2	China	1	1 (100)	IFN-κ
TMPRSS2 inhibitor (camostat mesylate)	Denmark	1	1 (100)	N/A
Tranilast	China	1	1 (100)	N/A
VIP	USA, Israel	1	1 (100)	N/A
vMIP	China	1	0 (0)	N/A
Meplazumab (anti-CD147)	China	1	1 (100)	N/A
Sodium Aescinate	China	1	1 (100)	N/A
Triazavirin	China	1	1 (100)	N/A

ACE: Angiotensin converting enzyme, Anti-PD-1 mAb: Anti Program Cell Death Protein-1 monoclonal antibody, ARBs: Angiotensin II receptor blockers, CD24Fc: CD24 extracellular domain-IgG1 Fc domain recombinant fusion protein, DRV/r or c: Darunavir/ritonavir or cobicistat, FTC/TAF: Emtricitabine/Tenofovir alafenamide, GM-CSF: Granulocyte Macrophage-Colony Stimulating Factor, hrIL-2: human recombinant interleukin 2, IFNα: Interferon alpha, IFNβ: Interferon beta, INFκ: Interferon kappa, IL: Interleukin, JAK: Janus Kinases, LPV/r: Lopinavir/ritonavir, M1: Type I Macrophage, N/A: Not applicable, RCTs: Randomised controlled trials, rhG-CSF: recombinant human Granulocyte-Colony Stimulating Factor, TCMs: Traditional Chinese Medicines, TMPRSS2: Transmembrane Protease Serine 2, TTF-2: Transcription Termination Factor 2, UK: United Kingdom, USA: United States of America, VIP: Vasoactive Intestinal Peptide, vMIP: viral Macrophage Inflammatory Protein.

888　　Table 2. Prevention interventions currently being evaluated for the novel coronavirus

889　　disease (COVID-19) globally.

Prevention intervention	Countries	No. of trials being tested	No. of RCTs (% of trials per intervention)	Other agents used in combination
TCMs	China	10	3 (30)	N/A
Antimalaria Drugs	China, USA, Mexico, UK, Spain	6	6 (100)	Umifenovir, DRV/c
Vaccine	USA, China	4	0 (0)	N/A
Health education	China, Hungary	3	2 (66.7)	TCM
IFNα1β	China	2	0 (0)	Thymosin a1
Darunavir/cobicistat	Spain	1	1 (100)	Chloroquine
Lopinavir/ritonavir	Canada	1	1 (100)	N/A
Mask	Canada	1	1 (100)	N/A
PUL-042	USA	1	1 (100)	N/A
Thymosin a1	China	1	0 (0)	IFNα1β
Umifenovir	China	1	1 (100)	Hydroxychloroquine

DRV/c: Darunavir/cobicistat, IFNα: Interferon alpha, LPV/r: Lopinavir/ritonavir, N/A: Not applicable, RCTs: Randomised controlled trials, TCMs: Traditional Chinese Medicines, UK: United Kingdom, USA: United States of America.

892   Table 3. Description of the clinical trials registered for the treatment and prevention of

893   COVID-19.

Study characteristics		Treatment studies	Prevention studies
		N = 198 (%)	N = 16 (%)
Study phase			
	Phase I	9 (5)	3 (19)
	Phase II*	31 (16)	2 (13)
	Phase III**	35 (18)	6 (38)
	Phase IV	40 (20)	1 (6)
	Unspecified	83 (42)	4 (25)
Study design			
	Randomised	150 (76)	10 (63)
	Non-randomised	21 (11)	3 (19)
	Single-arm	27 (14)	3 (19)
Blinding			
	Double-blind	31 (16)	6 (38)
	Single-blind	16 (8)	2 (13)
	Open-label	73 (37)	5 (31)
	Non-applicable†	29 (15)	3 (19)
	Unspecified	49 (25)	0 (0)
Total number of planned inclusions			
	<50	62 (31)	1 (6)
	50-100	41 (21)	0 (0)
	100-150	32 (16)	3 (19)
	150-200	9 (5)	0 (0)
	200-250	15 (8)	1 (6)
	≥250	39 (20)	11 (69)
Primary endpoint			
	Clinical	128 (65)	13 (81)
	Virological	39 (20)	2 (13)
	Radiological	19 (10)	0 (0)
	Immunological/biological	12 (6)	1 (6)

*Including phase I/II trials; **Including phase II/III trials; †: Single-arm or factorial trials.